Resistance to dual nucleoside reverse-transcriptase inhibitors in children infected with HIV clade A/E

被引:11
作者
Lolekha, R
Sirivichayakul, S
Siangphoe, U
Pancharoen, C
Kaewchana, S
Apateerapong, W
Mahanontharit, A
Chotpitayasunondh, T
Ruxrungtham, K
Phanuphak, P
Ananworanich, J
机构
[1] Thai Red Cross AIDS Res Ctr, Thailand Res Collaborat, Queen Sikrit Natl Inst Child Hlth, HIV NAT, Bangkok 10330, Thailand
[2] Chulalongkorn Univ, Bangkok 10330, Thailand
关键词
D O I
10.1086/427026
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The prevalence of nucleoside reverse-transcriptase inhibitor (NRTI) mutations was determined among 95 human immunodeficiency virus-infected Thai children who were treated with dual nucleoside reverse-transcriptase inhibitors. Almost all children had resistance to at least 1 NRTI, and approximately half of the children had resistance to multiple NRTIs. Cross-resistance to stavudine and azidothymidine was universal.
引用
收藏
页码:309 / 312
页数:4
相关论文
共 16 条
[1]  
Clavel F, 2004, NEW ENGL J MED, V350, P1023, DOI 10.1056/NEJM2ra025195
[2]  
D'Aquila Richard T., 2002, Top HIV Med, V10, P21
[3]  
de Mendoza Carmen, 2002, HIV Clin Trials, V3, P9
[4]   Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy [J].
Descamps, D ;
Flandre, P ;
Calvez, V ;
Peytavin, G ;
Meiffredy, V ;
Collin, G ;
Delaugerre, C ;
Robert-Delmas, S ;
Bazin, B ;
Aboulker, JP ;
Pialoux, G ;
Raffi, F ;
Brun-Vézinet, F .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 283 (02) :205-211
[5]   Diminished RNA primer usage associated with the L74V and M184V mutations in the reverse transcriptase of human immunodeficiency virus type 1 provides a possible mechanism for diminished viral replication capacity [J].
Diallo, K ;
Marchand, B ;
Wei, X ;
Cellai, L ;
Götte, M ;
Wainberg, MA .
JOURNAL OF VIROLOGY, 2003, 77 (16) :8621-8632
[6]   Efficacy of zidovudine compared to stavudine, both in combination with lamivudine and indinavir, in human immunodeficiency virus-infected nucleoside-experienced patients with no prior exposure to lamivudine, stavudine, or protease inhibitors (Novavir trial) [J].
Joly, V ;
Flandre, P ;
Meiffredy, V ;
Brun-Vezinet, F ;
Gastaut, JA ;
Goujard, C ;
Remy, G ;
Descamps, D ;
Ruffault, A ;
Certain, A ;
Aboulker, JP ;
Yeni, P .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (06) :1906-1913
[7]  
Masquelier B, 1999, ANTIVIR THER, V4, P69
[8]   Selection of zidovudine resistance mutations and escape of human immunodeficiency virus type 1 from antiretroviral pressure in stavudine-treated pediatric patients [J].
Maxeiner, HG ;
Keulen, W ;
Schuurman, R ;
Bijen, M ;
de Graaf, L ;
van Wijk, A ;
Back, N ;
Kline, MW ;
Boucher, CAB ;
Nijhuis, M .
JOURNAL OF INFECTIOUS DISEASES, 2002, 185 (08) :1070-1076
[9]   Antiretroviral drug resistance among HIV-1 infected children failing treatment [J].
Mullen, J ;
Leech, S ;
O'Shea, S ;
Chrystie, IL ;
du Mont, G ;
Ball, C ;
Sharland, M ;
Cottam, F ;
Zuckerman, M ;
Rice, P ;
Easterbrook, P .
JOURNAL OF MEDICAL VIROLOGY, 2002, 68 (03) :299-304
[10]   T69D/N pol mutation, human immunodeficiency virus type 1 RNA levels, and syncytium-inducing phenotype are associated with CD4 cell depletion during didanosine therapy [J].
Naugler, WE ;
Yong, FH ;
Carey, VJ ;
Dragavon, JA ;
Coombs, RW ;
Frenkel, LM .
JOURNAL OF INFECTIOUS DISEASES, 2002, 185 (04) :448-455